Abstract:Neuropsychiatric disorders affect millions of people globally. Despite their high prevalence, the precise molecular mechanisms behind these conditions remain largely unclear. A complex interplay of genetic, developmental, and environmental factors may increase susceptibility to these disorders, with specific molecular changes potentially influencing disease onset and progression. Understanding these molecular pathways is crucial for deepening our knowledge of neuropsychiatric pathophysiology and for developing targeted therapies. The Research Topic Molecular Mechanisms of Neuropsychiatric Diseases is the second volume and the continuation of the first volume [1], being created in response to the high interest and positive reception it received in the first volume.This research collection aims to uncover key molecular mechanisms in neuropsychiatric disorders and explore how they might inform therapeutic strategies. The progress in understanding these disorders has been slowed by a lack of clear anatomical and molecular mechanism understanding.The papers in this collection address these obstacles by connecting signs and symptoms to underlying anatomical and molecular alterations.The review by Azevedo et al examines how the activation of the sympathoadrenal medullary system and the hypothalamic-pituitary-adrenal axis in response to stress impacts memory formation, particularly in fear and traumatic memories linked to post-traumatic stress disorder (PTSD).Catecholamines like norepinephrine (NE) and epinephrine (EPI) play key roles in adaptive responses to stress and are involved in contextual fear memory enhancement through β2-adrenoceptor (β2-AR) activation [2], influencing the brain via the vagus nerve and blood glucose changes [3,4]. This review highlights that EPI is particularly influential in fear memories, activating the hippocampal Nr4a2 mRNA expression related to cAMP response element-binding protein (CREB), which plays a significant role in contextual fear memory consolidation under stressful conditions [5]. An imbalance in this system, especially over-active sympathetic responses, contributes to the persistence of traumatic memories in PTSD, with some patients [6] and animal PTSD models showing elevated catecholamine levels [7]. The authors suggest that treatments such as sotalol, a β-AR blocker [8], and nepicastat, a dopamine β-hydroxylase inhibitor [9], could reduce PTSD risk by preventing the consolidation of traumatic memories. These drugs appear to regulate gene expression in the hippocampus (Nr4a, Npas4 or Bdnf), potentially fostering more neutral contextual memories [8,9]. These treatment approaches, combined with therapy, may help PTSD patients build resilience and cope with trauma by down-regulating excessive catecholamine effects and dysregulated gene activity.A brief research report article by Bartsch et al investigates how traumatic stress leads to persistent neural changes, focusing on synaptic plasticity in a pathway between the neurons of the posterior ventral segment of the medial amygdala and the ventrolateral segment of the ventromedial hypothalamus. Using the mGRASP imaging technique, researchers observed an increase in synapse formation in this pathway in mice exposed to acute stress compared to controls. Chemogenetic inhibition of CaMKIIα-expressing neurons in the medial amygdala during stress reduced these synaptic changes, suggesting excitatory activity drives this plasticity. Additionally, blocking NMDA receptors prevented stress-induced synapse formation, highlighting an NMDA receptor-dependent mechanism. These structural changes in the medial amygdala and the ventromedial hypothalamus pathway may underlie lasting behavioural effects of traumatic stress, such as those seen in PTSD and social behaviour changes, shedding light on potential targets for intervention.affects stress responses, highlighting the role of dopaminergic neurotransmission in stress susceptibility and resilience. Researchers compared wild-type (WT) and DAT-knockout (KO) mice under chronic stress, observing that DAT-KO mice showed resistance to stress-related anxiety behaviours. These findings suggest that loss of DAT may protect against stress-induced anxiety-like behaviours, underscoring the significance of dopamine pathways in stress resilience.gene, which encodes a subunit of the GABAB receptor (GABABR) critical for inhibitory neurotransmission in the brain, impact receptor structure and function. A 7-year-old boy with Level 3 Autism Spectrum Disorder was found to carry a de novo GABBR2 p.Arg212Gln variant, identified as a variant of unknown significance via whole exome sequencing. Although treatment with the GABABR agonist baclofen showed no improvement, researchers investigated whether this variant might contribute to patient`s symptoms. Using molecular dynamics simulations and in vitro experiments, they studied how the p.Arg212Gln variant, along with -Abstract Truncated-

Transiently elevated expression of different forms of brain-derived neurotrophic factor in the neonatal medial prefrontal cortex affected anxiety and depressive-like behaviors in adolescence

Inhibiting Probdnf to Mature BDNF Conversion Leads to ASD-like Phenotypes in Vivo

Neonatal DEX Exposure Leads to Hyperanxious and Depressive-Like Behaviors As Well As a Persistent Reduction of BDNF Expression in Developmental Stages

Functional Role of BDNF Production from Unique Promoters in Aggression and Serotonin Signaling.

New Insights into BDNF Function in Depression and Anxiety

Brain-Derived Neurotrophic Factor Precursor in the Hippocampus Regulates Both Depressive and Anxiety-Like Behaviors in Rats.

Effects of BDNF Signaling on Anxiety-Related Behavior and Spatial Memory of Adolescent Rats in Different Length of Maternal Separation

BDNF and synaptic plasticity, cognitive function, and dysfunction.

H3K9me2 regulation of BDNF expression in the hippocampus and medial prefrontal cortex is involved in the depressive-like phenotype induced by maternal separation in male rats

Highly Penetrant Alterations of a Critical Region Including BDNF in Human Psychopathology and Obesity.

Brain-derived neurotrophic factor from microglia regulates neuronal development in the medial prefrontal cortex and its associated social behavior

Editorial: Molecular mechanisms of neuropsychiatric diseases, volume II

Regional Differences in the Expression of Brain-Derived Neurotrophic Factor (BDNF) Pro-Peptide, Probdnf and Preprobdnf in the Brain Confer Stress Resilience

Postnatal BDNF Expression Profiles in Prefrontal Cortex and Hippocampus of a Rat Schizophrenia Model Induced by MK-801 Administration

Variant Brain-Derived Neurotrophic Factor (BDNF) (met66) Alters the Intracellular Trafficking and Activity-Dependent Secretion of Wild-Type BDNF in Neurosecretory Cells and Cortical Neurons

Depression-like Behavior and Change in Hippocampus BDNF Mrna Expression Induced by Early Deprivation in Rats

Lack of Association Between the BDNF C270T Polymorphism and Schizophrenia in a Chinese Han Population

BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder.

Requirements of Postnatal proBDNF in the Hippocampus for Spatial Memory Consolidation and Neural Function

Effects of Adolescent Social Isolation on the Expression of Brain-Derived Neurotrophic Factors in the Forebrain.

BDNF Overexpression in the Ventral Hippocampus Promotes Antidepressant- and Anxiolytic-Like Activity in Serotonin Transporter Knockout Rats